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pediatric versus adult randomized trials: a
meta-epidemiologic empirical evaluation
Ben Vandermeer1, Ingeborg van der Tweel2, Marijke C. Jansen-van der Weide3, Stephanie S. Weinreich3,4,
Despina G. Contopoulos-Ioannidis5,6, Dirk Bassler7, Ricardo M. Fernandes8,9, Lisa Askie10, Haroon Saloojee11,
Paola Baiardi12, Susan S. Ellenberg13 and Johanna H. van der Lee3*
Abstract
Background: We wished to compare the nuisance parameters of pediatric vs. adult randomized-trials (RCTs) and
determine if the latter can be used in sample size computations of the former.
Methods: In this meta-epidemiologic empirical evaluation we examined meta-analyses from the Cochrane Database
of Systematic-Reviews, with at least one pediatric-RCT and at least one adult-RCT. Within each meta-analysis
of binary efficacy-outcomes, we calculated the pooled-control-group event-rate (CER) across separately all
pediatric and adult-trials, using random-effect models and subsequently calculated the control-group event-rate
risk-ratio (CER-RR) of the pooled-pediatric-CERs vs. adult-CERs. Within each meta-analysis with continuous outcomes we
calculated the pooled-control-group effect standard deviation (CE-SD) across separately all pediatric and adult-trials and
subsequently calculated the CE-SD-ratio of the pooled-pediatric-CE-SDs vs. adult-CE-SDs. We then calculated across
all meta-analyses the pooled-CER-RRs and pooled-CE-SD-ratios (primary endpoints) and the pooled-magnitude of
effect-sizes of CER-RRs and CE-SD-ratios using REMs. A ratio < 1 indicates that pediatric trials have smaller nuisance
parameters than adult trials.
Results: We analyzed 208 meta-analyses (135 for binary-outcomes, 73 for continuous-outcomes). For binary outcomes,
pediatric-RCTs had on average 10% smaller CERs than adult-RCTs (summary-CE-RR: 0.90; 95% CI: 0.83, 0.98). For mortality
outcomes the summary-CE-RR was 0.48 (95% CIs: 0.31, 0.74). For continuous outcomes, pediatric-RCTs had on average
26% smaller CE-SDs than adult-RCTs (summary-CE-SD-ratio: 0.74).
Conclusions: Clinically relevant differences in nuisance parameters between pediatric and adult trials were detected.
These differences have implications for design of future studies. Extrapolation of nuisance parameters for sample-sizes
calculations from adult-trials to pediatric-trials should be cautiously done.
Keywords: Nuisance parameters, Extrapolation, Sample size computations, Pediatric trials, Adult trials
Background
For sample size calculations for randomized controlled tri-
als (RCTs), some parameters, like the treatment difference
(effect size) between the experimental and control inter-
vention have to be estimated. The investigators also have
to estimate parameters that are not of direct interest, but
are required for the computations. These parameters are
often termed nuisance parameters, the most common of
which are the control-group event rate (CER) for binary
outcomes and the standard deviation (SD) for continuous
outcomes.
Determining an appropriate sample size for an RCT
has always been a challenge due to these nuisance
parameters being unknown and needing to be estimated
[1, 2]. Usually, they can only be estimated from previous
studies on the same topic, but there is always a problem
when the new study is the first trial on the topic.
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Consequences of erroneously estimated nuisance pa-
rameters are the under-estimation or over-estimation
of the required sample size, which can then lead to
underpowered studies that may fail to reach a defini-
tive conclusion [3] in the former case, or to unneces-
sary higher study cost and longer recruitment periods
in the latter case [4].
Investigators sometimes extrapolate evidence on
nuisance parameters from randomized trials in adults
for sample size calculations in pediatric trials [1, 5, 6].
However, differences in clinical effects between adults
and children do exist as has been previously shown by
systematic empirical evaluations of the comparative
effectiveness and comparative safety of medical interven-
tions between adults and children [7–10]. A systematic
empirical evaluation of nuisance parameters in pediatric
RCTs, as compared to adult RCTs has not been previ-
ously performed.
We performed a meta-epidemiologic empirical evalua
tion to investigate whether nuisance parameters differ
between pediatric and adult trials on the same topics,
for the same compared interventions and for the same
clinical outcomes. We also studied whether there are dif-
ferences in the nuisance parameters according to the
types of outcomes: binary versus continuous efficacy
outcomes and mortality versus non-mortality outcomes.
Methods
Selection of meta-analyses
We addressed the above questions by examining 106
systematic reviews from the Cochrane Database of
Systematic Reviews (CDSR) (Issue 1, 2007), that have
been previously analyzed [9] in an empirical evaluation
of the comparative effectiveness of medical interventions
in children versus adults. These systematic reviews
included 135 meta-analyses on diverse medical interven-
tions with binary efficacy outcomes with at least one
adult RCT and at least one pediatric RCT per meta-
analysis. In this prior analysis, the following types of
meta-analyses were excluded: those involving surgical,
psychological, behavioral, social interventions, or evalua-
tions of medical devices; those focusing exclusively on
harms, without any primary efficacy outcome; meta-
analyses with only continuous outcomes; meta-analyses
for which it was not possible to discriminate between an
experimental and control intervention; those without
any quantitative data synthesis and those that did not
cover both age groups and did not have any complemen-
tary systematic review focusing on the other age group.
When a systematic review addressed different types of
eligible comparisons of experimental versus control
interventions, each comparison was considered for
eligibility separately [9].
We further screened these 106 systematic reviews to
identify additional eligible meta-analyses with continu-
ous outcomes that had included at least one adult RCT
and at least one pediatric RCT per meta-analysis.
Furthermore, we screened 79 reviews previously ex-
cluded in the Contopoulos-Ioannidis et al. study since
they did not contain binary efficacy primary outcomes.
Four authors (BV, IT, MJW, and SW) extracted all
continuous-outcome meta-analyses up to a maximum of
five per review—if more than five continuous-outcome
meta-analyses were reported we chose the five meta-
analyses that had the maximum number of participants.
We excluded meta-analyses that used a standardized
mean difference as their method of pooling, since these
standard deviations would be expected to be different
(i.e. different scales for different trials). A total of 73
continuous-outcome meta-analyses (from both sources)
were included in our continuous-outcome analysis
(Fig. 1).
Data extraction
From each eligible meta-analysis with binary efficacy
outcomes we extracted the following data from the in-
cluded RCTs: a) compared interventions (experimental
vs. control); b) event rate (events/total) in the control
group; c) control group sample size and d) age group of
study participants (adults versus children). From each
eligible meta-analysis with continuous outcomes we
extracted the following study level data: a) standard
deviation of effect-size in the control group; b) control
group sample size; c) mean of effect size in the control
group and d) age group of study participants. For the
identification of the experimental and control interven-
tion when two active interventions were compared we
used the interpretation of the authors of the Cochrane re-
view. For the study age group categorization, we used the
classification reported in the Cochrane review. If this was
not described, we used age group classification rules previ-
ously applied by Contopoulos-Ioannidis et al. In brief, a
study was characterized as “adult” if all included patients
were >12 years and patients >20 years were also included;
“pediatric” if all patients were <20 years and patients
<12 years were also included.
Data synthesis
Primary endpoints
Binary efficacy outcomes
Pooling of CER- risk ratios (summary-CER-RRs): First, we
calculated the CER by dividing the event rate in the
control group by the total sample size in the control
group for each individual study. Second, for each of
these CERs we calculated its standard error using the
normal scores method [11]. Third, separately for all
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pediatric and adult RCTs, we used a random effects
model [12] within each meta-analysis to estimate a
pooled-pediatric-CER and pooled-adult-CER respectively,
its standard error and the heterogeneity statistic I-squared
[13]. Fourth, for each meta-analysis, we computed the
logarithm of the CER-RR of the pediatric CER to the adult
CER with its associated standard error. Finally, we
calculated the summary-CER-RR between pediatric and
adult trials and their 95% confidence intervals across all
meta-analyses by synthesizing the pooled logarithms of
the CER-RRs within each meta-analysis again using the
random effects model [14]. The logarithms were con-
verted back to CER-RRs for presentation purposes. A
CER-RR < 1 indicated that pediatric trials had smaller
CERs than adult trials.
Exploratory analyses
Pooling of magnitude of absolute CER-RRs: Here our
interest was in the magnitude of difference in estimated
nuisance parameters, not the direction. The pooling of
the CERs as described above takes into account also
directional differences in CER-RRs between pediatric
and adult studies—thus, a minimal estimated difference
in that analysis would not reduce concerns about the
comparability of nuisance parameters in any individual
situation. Therefore, it was important to assess also the
magnitude of the differences by performing a separate
meta-analysis of the “absolute CER-RRs”. The method-
ology was the same as above, except that before the final
step of pooling the CER-RRs, we replaced any RR
smaller than 1 with its reciprocal. This is mathematically
equivalent to replacing the logarithm of the RR in the
final meta-meta-analysis with its absolute value. This
pooled estimate tells us how large (on average) the CER-
RRs were, regardless of which group (pediatric or adult)
had the larger CER. For example, CER-RRs of 1.25 and
0.80 will be transformed to absolute CER-RRs of 1.25
and 1.25 respectively.
Subgroup analysis
The binary-outcome meta-analyses were sub-grouped by
mortality and non-mortality outcomes. We computed a
separate summary–CER-RR for each of these groups.
Fig. 1 Flowchart
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Continuous efficacy outcomes
Pooling of control group-effect-SD-ratios (CE-SD-ratios):
First, we extracted the SD of the estimate in the control
group of each pediatric and adult RCT. Second, we
calculated the weighted average of the SDs for all
pediatric (pooled-pediatric-CE-SD) and adult RCTs
(pooled-adult-CE-SD), respectively, within each meta-
analysis, by weighting with the square root of each
study’s sample size. Third, we computed the ratio [CE-
SD-ratio] of the pediatric vs. adult control-group effect-
SDs within each meta-analysis by dividing the weighted-
average-pediatric SDs (pooled-pediatric-CE-SD) by the
weighted-average-adult SDs (pooled-adult-CE-SD). Fi-
nally, we calculated the summary-CE-SD-ratio between
pediatric and adult trials across all meta-analyses as the
weighted average of the logarithms of these ratios. The
summary log SD ratio was exponentiated to get the
summary CE-SD-ratio. A CE-SD-ratio < 1 indicates that
pediatric trials had smaller SDs than adult trials.
Descriptive analyses
For graphical comparison of the CE-SDs of adult vs.
pediatric RCTs within each meta-analysis we divided the
CE-SDs of each individual RCT by the maximum SD in
that meta-analysis in order to get a standardized CE-SD
for each adult and pediatric RCT that would allow com-
parisons of adult and pediatric CE-SDs within each
meta-analysis and across meta-analyses.
Software
Summary statistics and weighted averages were computed
in SAS 9.3 (SAS institute Inc., Cary NC). Meta-analyses
were performed using the metan module in Stata 11.2
(StataCorp, College Station TX). Graphs were produced
using Review Manager, SPlus 8.2 (Tibco Software Inc.),
and Microsoft Excel.
Results
We examined 208 meta-analyses, 135 with binary
primary efficacy outcome data and 73 with continuous
outcome data, from a total of 185 systematic reviews. All
meta-analyses comprised a total of 2110 RCTs; 1515
adult RCTs (1126 with binary and 389 with continuous
outcomes) and 595 pediatric RCTs (355 with binary and
240 with continuous outcomes). Each study could have
contributed data to more than one meta-analysis within
each systematic review (e.g. for different meta-analyses
with different compared interventions or outcomes).
Binary outcome analyses
Summary pooled-CER-RRs
The summary-pooled-CER-RR of pediatric CERs versus
adult CERs across all 135 meta-analyses showed that
pediatric RCTs had on average a 10% smaller CERs
Fig. 2 Distribution across all meta-analyses of the CER-Risk Ratios of
the logarithmically transformed pooled-pediatric-CERs vs. pooled-adult-
CERs per meta-analysis
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(summary-CER-RR: 0.90; 95% CI: 0.83, 0.98). The indi-
vidual CER-RRs within each meta-analysis are shown in
Fig. 2 and their distribution thereof in Fig. 3. Overall,
13.3% of the examined meta-analyses had pediatric-
CERs that were at least five-fold smaller than the adult-
CERs; the opposite (adult RCTs with at least five-fold
smaller CERs than pediatric RCTs) occurred in only
2.2% of cases. Moreover, in 60.7% of the meta-analyses,
the pediatric-CERs were smaller than the adult-CERs.
I2 values were calculated for 172 of the 270 meta-
analyses (135 each for pediatric and adult trials respect-
ively); for the remaining meta-analyses, I2 was not
defined as they included only single studies. The distri-
bution of these I2 values within each meta-analysis is
shown in Table 1. Since these meta-analyses do not mix
pediatric and adult data, these results show high hetero-
geneity among studies even when the pediatric/adult
factor was taken out of the analysis.
Subgroup analysis: Mortality and non-mortality outcomes
There were 21 meta-analyses with mortality outcomes
and 114 meta-analyses with non-mortality outcomes.
Among the 21 meta-analyses with mortality outcomes
the summary-pooled CER-RRs of pediatric-CERs vs.
adult-CERs was 0.48 (95% CI: 0.31, 0.74). In 18 of these
21 meta-analyses the mortality CER in adult trials was
larger than that in pediatric trials.
Among the 114 meta-analyses with non-mortality out-
comes the summary-CER-RR of pediatric vs. adult trials
was 1.00 (95% CI: 0.92, 1.09).
Pooling using magnitude (absolute CER-RR)
When we repeated the primary analysis using the
“absolute-CER-RR” (Fig. 4) instead of the CER-RR the
summary–absolute-CER-RR was 1.46 (95% CI; 1.37,
1.56). This indicates that CERs in pediatric trials are on
average either 1.5 times larger or 1.5 times smaller than
in adult trials.
Continuous outcome analyses
Summary-pooled-CE-SD-ratios
The weighted average (weighted on the log scale by the
square root of the sample size) (summary-CE-SD-ratio)
of the CE-SD-ratios of pediatric-CE-SDs vs adult-CE-
SDs for the 73 meta-analyses with continuous efficacy
outcomes was 0.74. This indicates that on average the
pediatric RCTs CE-SDs were 26% smaller than their
adult counterparts. The distribution of the CE-SD-ratios
is shown in Fig. 5. In 27.1% of the meta-analyses the CE-
SD-ratios between pediatric and adult RCTs differed by
at least 2-folds in either direction. Furthermore, ignoring
direction of difference, and looking only at the sizes, the
weighted magnitude of CE-SD-ratio was 1.76, which
means that, on average, the CE-SD in adult and pediatric
RCTs differed by a factor of 1.76.
The distribution of the standardized SDs of the effect
sizes in the control groups of all adult and pediatric
studies within each meta-analysis is shown in Fig. 6. The
SDs of the effect sizes in the control groups of pediatric
vs. adult trials varied greatly both within meta-analyses
and between meta-analyses.
Discussion
The control-group event rate nuisance parameter in
pediatric trials was on average 10% smaller than that in
adult trials. In our secondary analyses, when we consid-
ered the magnitude of the control-group effect size
rather than the direction of effect, pediatric trials had an
average control-group event rate that was 1.5 times
higher or 1.5 times smaller than that in adult RCTs. The
reason for considering also the magnitude of effects, ig-
noring their direction thereof, is that an important issue
Fig. 3 Distribution of CER-RR within each meta-analysis
Table 1 Distribution of I2 values across meta-analyses
I-squared Number of meta-analyses (%)
0% 30 (17%)
0–20 7 (4%)
20–40 5 (3%)
40–60 15 (9%)
60–80 32 (19%)
80–100 83 (48%)
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to address is whether nuisance parameters in pediatric
studies are likely to differ from those estimated from
adult studies. We could have large differences in nuis-
ance parameters (some over-estimating, some under-
estimating) that average out to no difference. By analyz-
ing magnitudes, we are pre-supposing a difference and
trying to estimate how large that difference might be.
In over 60% of meta-analyses the control-group event
rates in pediatric RCTs were smaller than those in adult
trials and in 36% of the meta-analyses, relative differences
in control-group event rates of at least 2-folds, in either
direction, were identified. Specifically, for mortality
outcomes, the control-group mortality rate in pediatric
trials was on average 50% lower than that in adult trials.
Large variation was also seen between pediatric and
adult trials when continuous efficacy outcomes were
considered. The pediatric control-group SD was on aver-
age 26% smaller than that of adult trials and in 27% of
the meta-analyses the relative difference in SDs between
pediatric and adult trials was at least 2-fold in either
direction. Moreover, when the magnitude of the control-
group SD was considered, pediatric trial SDs were at
least either 1.8 times larger or 1.8 times smaller than
adult trial SDs.
Large differences were seen among many studies with
regards to nuisance parameters. To demonstrate how
erroneous estimation of nuisance parameters can affect
sample size computation substantially, we will take two
examples from the included meta-analyses in this study.
In the review Antibiotics for the common cold and acute
purulent rhinitis, for the primary meta-analysis of the
persisting symptoms outcome, we had an estimated CER
in the adult population of 0.48. If one wishes to conduct
a pediatric trial on the same topic, with a type I error
probability of 0.05, 80% power, and an assumption that a
30% reduction in number of patients with persisting
symptoms would be required to demonstrate a clinically
relevant antibiotic effect, the required sample size for
the pediatric study would be 182 patients per arm.
Under the assumption of a CER of 0.048, as was actually
seen in the pediatric trials, the required sample size
would be over 16 times larger at 2962. To give an ex-
ample using a continuous outcome, we take the review
Early emergency department treatment of acute asthma
with systemic corticosteroids. For the outcome of final
PEFR, we had observed a mean SD in the adult studies
of 32 L/min. Suppose we plan to conduct a pediatric
trial on the same topic, using a type I error probability
of 0.05, a power of 80%, and a minimal clinical import-
ant difference threshold of 15 L/min. Using the adult
estimated SD of 32 L/min, we could compute that we
would require 643 patients in each of two groups. If we
assume an SD estimate of 4.3 L/min, as was observed in
the pediatric trials, we would only require a sample of
Fig. 4 Distribution of the absolute values of the CER-Risk Ratios of
the logarithmically transformed pooled-pediatric-CERs vs. pooled-adult
CERs per meta-analysis
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12 patients in each group, a sample size that is less than
2% of the originally computed sample size. It is clear
from these examples that the erroneous estimations of
these nuisance parameters can have important implica-
tions in the sample size computations, which can lead to
either inappropriately powered studies that would not be
able to answer the clinical question, or, on the other
hand, to unnecessary waste of valuable clinical and
financial resources. A third unwanted consequence
might be that a proposed trial is not conducted because
the erroneous estimate for the sample size is too large to
be feasible.
We did observe a trend in both binary and continuous
outcome data for pediatric RCTs to have smaller values
of nuisance parameters (both CERs and CE-SDs) than
their adult counterparts. Thus, when one does use these
parameters from adult studies as surrogate for pediatric
studies, the nuisance parameter is more likely to be
overestimated than underestimated. This relationship
has been well documented and graphed2. In the case of
continuous data, an overestimation of the SD will always
result in an overestimation of the sample size. The
situation for binary data is more nuanced, as the sample
size will depend upon the ratio of the CER and the
treatment-group event rate (the closer the ratio is to 1,
the larger the required sample size), so an underestima-
tion of the CER could lead to either an under- or overes-
timated sample size. For example, if a pediatric
population had an actual CER of 0.3 with a treatment-
group event rate of 0.2, then underestimating the CER
(say as 0.25) would result in a larger than required sam-
ple. However; if the treatment-group event rate was 0.4,
then this underestimate of the CER would result in a
sample that was too small.
The discrepancies in the nuisance parameters between
pediatric and adult trials were more prominent with
mortality outcomes. In 86% of meta-analyses with
mortality outcomes, the mortality CER in adult trials
was larger than that in pediatric trials. On average, the
control-group mortality rates in adult trials were two
times larger than in pediatric trials. Mortality seems to
be an outcome where extrapolation of adult control-
group event rates for the estimation of pediatric trial
sample sizes may give inaccurate results.
We should acknowledge some study limitations. Trad-
itional meta-analysis of standard deviations was not feas-
ible in the analysis of continuous outcomes since the
systematic reviews did not provide us enough information
to ascertain variances around these nuisance parameters.
Meta-analyses were done on a variety of outcomes, and
thus the standard deviations were all reported in different
units, and therefore not comparable across meta-analyses
without standardization. In both the analyses of binary
and continuous outcomes we observed considerable het-
erogeneity in nuisance parameters, not only between
meta-analyses but also within them. We assumed that
studies included within the same meta-analysis of a
Cochrane review would have populations sufficiently simi-
lar to use them to impute nuisance parameters. However,
extremely high between-study heterogeneity (I2 > 80%)
was seen in more than half of the meta-analyses, which
implies that even within studies of the same age-group
(i.e. adult or pediatric) we cannot expect nuisance parame-
ters to routinely be similar. This suggests that not only
should we be wary of extrapolating nuisance parameters
for pediatric studies from adult studies, but we should be
almost equally wary of extrapolating them from other
pediatric studies.
With these limitations in mind and given the results
we have seen here, it would be interesting to do a
further and more refined analysis as to which factors
may lead to better concordance between the nuisance
parameters of pediatric and adult studies. This would be
a difficult endeavor, however, since these factors would
likely be specific to a subject area, and not necessarily
generalizable. Analysis would then have to be limited to
those areas where there are enough studies to do it
properly.
Conclusion
This study provides evidence to raise awareness among
investigators planning to design trials in children, when
available data on nuisance parameters are mostly from
adult studies that significant differences between pediatric
Fig. 5 Summary of CE-SD ratios of pooled-pediatric-CE-SDs vs. pooled-adult-CE-SDs (within each meta-analysis)
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and adult trials do exist. Extrapolation from adult trials of
nuisance parameters to guide sample size calculations for
pediatric trials should be cautiously done. Inappropriate
extrapolations of nuisance parameters from adult trials to
pediatric trials can lead to erroneous sample size calcula-
tions. Significant over- or underestimation of the required
pediatric sample sizes can occur particularly when the
outcome is mortality. When there is doubt about the simi-
larity between the population from which the estimates
are derived and the prospective study population, either a
blinded sample size review during the early phase of the
new trial (internal pilot study [15]), a more flexible
(sequential) design and analysis [1, 2], or use of a stan-
dardized effect size [16] should be considered to maximize
trial efficiency.
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